Publications by authors named "Guilherme Nader-Marta"

Claim this Profile
P
PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial.
Martin Manley, Guilherme Nader-Marta, Ayça Arcay Ozturk, Mutaz Kassas, Francoise Rothé

Eur J Nucl Med Mol Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.
Karen Van Baelen, Ha-Linh Nguyen, François Richard, Gitte Zels, Maria Margarete Karsten, Guilherme Nader-Marta

Breast Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404].
M Sirico, F Jacobs, C Molinelli, Guilherme Nader-Marta, V Debien

Crit Rev Oncol Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino

Breast Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Diogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, Lieveke Ameye, Evandro de Azambuja

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.
M Sirico, F Jacobs, C Molinelli, Guilherme Nader-Marta, V Debien

Crit Rev Oncol Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Veronique Debien, Elisa Agostinetto, Marco Bruzzone, Marcello Ceppi, Diogo Martins-Branco, Guilherme Nader-Marta

Clin Breast Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2023 Year in review: Early breast cancer.
Guilherme Nader-Marta, Ann H Partridge

Breast· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Suppression: Early Menopause and Late Effects.
Chiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, Roberto Borea, Graziana Scavone

Curr Treat Options Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.
François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada, Guilherme Nader-Marta

Expert Opin Drug Metab Toxicol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis.
Flavia Jacobs, Chiara Molinelli, Diogo Martins-Branco, Guilherme Nader Marta, Maurine Salmon

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.
Diogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos, Philippe Barthelemy, Anthony Goncalves

Nat Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
Alex De Caluwe, Emanuela Romano, Philip Poortmans, Andrea Gombos, Elisa Agostinetto

J Immunother Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Diogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, Lieveke Ameye, Marianne Paesmans

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Veronique Debien, Guilherme Nader Marta, Elisa Agostinetto, Marianna Sirico, Flavia Jacobs

Crit Rev Oncol Hematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA in breast cancer: a biomarker for patient selection.
Elisa Agostinetto, Guilherme Nader-Marta, Michail Ignatiadis

Curr Opin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
Karen Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, François Richard, Maria Margarete Karsten

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
Diogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, Veronique Debien, Lieveke Ameye

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien, Diogo Martins-Branco, Philippe Aftimos

Ther Adv Med Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer.
Renata Colombo Bonadio, Fabiano de Almeida Costa, Sofia Vidaurre Mendes, Breno Jeha Araujo, Guilherme Nader-Marta

Clin Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma.
Rodrigo R Munhoz, Guilherme Nader-Marta, Veridiana P de Camargo, Marcello M Queiroz, Jade Cury-Martins

Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica

Br J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Elisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, Lieveke Ameye, Isabelle Veys

Future Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, Armando Santoro, Kevin Punie

Expert Opin Investig Drugs· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis